
PCVX
Vaxcyte Inc.
$30.79
+$0.02(+0.06%)
28
Overall
--
Value
30
Tech
26
Quality
Market Cap
$3.93B
Volume
944.90K
52W Range
$27.66 - $121.06
Target Price
$114.88
Order:
Income Statement
Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|
OPERATING EXPENSES | |||||||
Operating Expenses | $89.6M | $103.7M | $232.3M | $468.0M | $569.5M | ||
Research & Development | $73.6M | $78.4M | $169.5M | $332.3M | $476.6M | ||
Research Expense | $73.6M | $78.4M | $169.5M | $332.3M | $476.6M | ||
Selling, General & Administrative | $16.0M | $25.3M | $39.8M | $60.7M | $92.9M | ||
General & Administrative Expenses | $16.0M | $25.3M | $39.8M | $60.7M | $92.9M | ||
Depreciation & Amortization | $1.4M | $1.8M | $2.6M | $3.2M | $7.0M | ||
Depreciation & Amortization | $1.4M | $1.8M | -- | -- | -- | ||
Other Operating Expenses | $-287.0K | $-461.0K | -- | -- | -- | ||
OPERATING INCOME | |||||||
Operating income | $-89.6M | $-103.7M | $-232.3M | $-468.0M | $-569.5M | ||
EBITDA | $-87.8M | $-96.6M | $-214.3M | $-392.1M | $-448.1M | ||
NON-OPERATING ITEMS | |||||||
Interest Expense (Non-Operating) | $7.0K | $7.0K | $2.0K | -- | -- | ||
Intinc | $244.0K | $344.0K | $8.4M | $62.9M | $110.0M | ||
Net Non-Operating Interest Income/Expense | $237.0K | $337.0K | $8.4M | $62.9M | $110.0M | ||
Gain on Sale of Securities | -- | $2.0K | -- | -- | -- | ||
Other Income/Expense | $-2.5M | $-1.6M | $-24.5M | $-2.9M | $4.4M | ||
Other Special Charges | $2.5M | $1.6M | -- | $2.9M | $-4.4M | ||
SPECIAL ITEMS | |||||||
Special Income Charges | $-267.0K | -- | $-213.0K | -- | -- | ||
Impairment of Capital Assets | $267.0K | -- | -- | -- | -- | ||
PRE-TAX INCOME | |||||||
EBIT | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
Pre-Tax Income | $-89.2M | $-100.1M | $-223.5M | $-327.3M | $-463.9M | ||
NET INCOME | |||||||
Net Income | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
Net Income (Continuing Operations) | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
Net Income (Discontinued Operations) | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
Net Income (Common Stockholders) | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
TOTALS | |||||||
Total Expenses | $89.6M | $103.7M | $232.3M | $468.0M | $569.5M | ||
SHARE & EPS DATA | |||||||
Average Shares Outstanding | $29.5M | $51.9M | $64.9M | $97.2M | $122.0M | ||
Average Shares Outstanding (Diluted) | $29.5M | -- | $64.9M | $97.2M | $122.0M | ||
Shares Outstanding | $51.3M | $56.3M | $80.0M | $108.4M | $128.8M | ||
Basic EPS | $-3.02 | $-1.93 | $-3.44 | $-4.14 | $-3.8 | ||
Basic EPS (Continuing Operations) | $-3.02 | $-1.93 | $-3.44 | $-4.14 | $-3.8 | ||
Diluted EPS | $-3.02 | $-1.93 | $-3.44 | $-4.14 | $-3.8 | ||
Diluted EPS (Continuing Operations) | -- | -- | $-3.44 | $-4.14 | $-3.8 | ||
OTHER METRICS | |||||||
Gain On Sale Of P P E | -- | -- | $-44.0K | -- | -- | ||
Other Gand A | $16.0M | $25.3M | $39.8M | $60.7M | $92.9M | ||
Rent And Landing Fees | $700.0K | -- | -- | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | PCVX | $30.79 | +0.1% | 944.90K |
3 | ||||
4 | ||||
5 | ||||
6 |